Replies to post #384702 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Well Done,

powerwalker

TGD has stated @ Guggenheim that the higher dose of 50mg showed cognitive improvement in PDD participants and then said that dose was used in the AD P2b/3 trial. Meanwhile, he noted 30 mg stopped the decline in PDD; same dose used in AD trial, too.

[ckent]

Exactly, Missling has always been very conservative and careful when speaking about efficacy, maybe not so much with timelines, but definitely very tempered when speaking of efficacy. During conferences before the P2a and OLE, he would hedge saying things like he was "cautiously optimistic." He has stopped doing this. He no longer uses hedge phrases nor needs to hedge since he's just stating facts based on previous trials.

He wants us to remember facts. "I want you to remember the numbers of the doses here for a reason... placebo declined... the medium dose stopped the decline... but the high dose group was above baseline... so patients coming into the trial came out with better cognitive features. And the reason I want you to remember these doses is that it's exactly the same doses as in the upcoming Alzheimer's study. Placebo, thirty, fifty." Facts!

[Investor2014]

Yes but not for all patients in each arm. How many patients in each arm is the big question that drives the p-value of the outcome.

[LakeshoreLeo1953]

Even after a XC flight I can deconstruct Missling's statement to mean a single (perhaps even multiple) patient dosed @ 30mg stopped decline. Same applies for 50mg "meaning".
It does not mean either outcome is universal.